Share on StockTwits

Insulet (NASDAQ:PODD) Insider Peter Devlin sold 12,314 shares of the company’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $37.10, for a total transaction of $456,849.40. Following the transaction, the insider now directly owns 67,354 shares of the company’s stock, valued at approximately $2,498,833. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Insulet (NASDAQ:PODD) traded down 3.56% during mid-day trading on Tuesday, hitting $37.61. 992,295 shares of the company’s stock traded hands. Insulet has a 1-year low of $28.73 and a 1-year high of $51.31. The stock’s 50-day moving average is $36.53 and its 200-day moving average is $40.76. The company’s market cap is $2.084 billion.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.05. The company had revenue of $69.20 million for the quarter, compared to the consensus estimate of $68.47 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. The company’s revenue for the quarter was up 20.6% on a year-over-year basis. On average, analysts predict that Insulet will post $-0.14 earnings per share for the current fiscal year.

A number of research firms have recently commented on PODD. Analysts at Barrington Research upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 15th. They now have a $40.00 price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Insulet from $60.00 to $50.00 in a research note on Friday, May 9th. Finally, analysts at Leerink Swann cut their price target on shares of Insulet from $55.00 to $45.00 in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $43.36.

Insulet Corporation is primarily engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (NASDAQ:PODD).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.